Protalix BioTherapeutics logo

Protalix BioTherapeuticsNYSE American: PLX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

15 May 1998

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$91.19 M
-58%vs. 3y high
42%vs. sector
-vs. 3y high
-vs. sector
-98%vs. 3y high
71%vs. sector
-55%vs. 3y high
41%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:39:56 GMT
$1.24+$0.04(+3.33%)

Dividend

No data over the past 3 years
$13.47 M$16.26 M
$13.47 M-$2.20 M

Analysts recommendations

Institutional Ownership

PLX Latest News

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024
globenewswire.com16 September 2024 Sentiment: POSITIVE

The Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results
prnewswire.com14 August 2024 Sentiment: POSITIVE

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2024, and provided a business update.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
accesswire.com11 June 2024 Sentiment: NEGATIVE

PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE:PLX) ("Protalix") on behalf of the company's shareholders. Since May 2023, shares of Protalix common stock have declined in value from a trading price of approximately $3.25 per share to a current trading price of below $1.25 per share, a decline of over 61% in value.

Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript
Seeking Alpha14 March 2024 Sentiment: POSITIVE

Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
PRNewsWire23 February 2024 Sentiment: POSITIVE

Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET CARMIEL, Israel , Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City. Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 1:00 PM ET at the Plymouth Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees.

Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023
PRNewsWire31 July 2023 Sentiment: NEUTRAL

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023.

Protalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive Profitability
Seeking Alpha30 May 2023 Sentiment: POSITIVE

Protalix received FDA and EU approval for Elfabrio. This puts the company on track for profitability as early as 2023. With a reasonable valuation and strong growth, I see a significant potential upside for PLX stock.

What type of business is Protalix BioTherapeutics?

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

What sector is Protalix BioTherapeutics in?

Protalix BioTherapeutics is in the Healthcare sector

What industry is Protalix BioTherapeutics in?

Protalix BioTherapeutics is in the Biotechnology industry

What country is Protalix BioTherapeutics from?

Protalix BioTherapeutics is headquartered in Israel

When did Protalix BioTherapeutics go public?

Protalix BioTherapeutics initial public offering (IPO) was on 15 May 1998

What is Protalix BioTherapeutics website?

https://www.protalix.com

Is Protalix BioTherapeutics in the S&P 500?

No, Protalix BioTherapeutics is not included in the S&P 500 index

Is Protalix BioTherapeutics in the NASDAQ 100?

No, Protalix BioTherapeutics is not included in the NASDAQ 100 index

Is Protalix BioTherapeutics in the Dow Jones?

No, Protalix BioTherapeutics is not included in the Dow Jones index

When was Protalix BioTherapeutics the previous earnings report?

No data

When does Protalix BioTherapeutics earnings report?

The next expected earnings date for Protalix BioTherapeutics is 06 November 2024